Projected commercial pricing When Eli Lilly eventually brings retatrutide to market, likely in late 2027 or 2028, analysts project a list price of $1,000 to $1,500 per month based on comparable GLP-1 medications like Mounjaro and Ozempic
Survodutide , another GLP-1/glucagon dual agonist from Boehringer Ingelheim, is advancing through clinical trials
See best peptides for weight loss for a broader ranking
Amini A, Hamann S, Larsen M
The front page had me (pulled from social media) on the cover with a headline Grant said
For anyone who wants to try GLP1s treatment without locking themselves into a contract, MEDVi hits the right balance between affordability and the level of medical support that makes a real difference, especially in the early months of treatment